Everolimus – USA

Everolimus – USA

IPR decision (Jan 11, 2018):
AIA Review
Filing Date
Institution Date
Petitioner
Patent No.
Status
IPR2016-00084
10/26/2015
04/29/2016
Par Pharmaceutical, Inc.
US 5,665,772
Final Written Decision (claims 1–3 and 8–10 are patentable)
Roxane, Breckenridge IPRs (IPR2016-01102 & IPR2016-01023) were terminated as they joined above IPR & Par, Breckenridge’s IPRs (IPR2016-01059 & IPR2016-01103) were denied.
US 5,665,772 patent claims compound.
Leave a Reply

Leave a Reply

Your email address will not be published.

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2022 Pharma IP Circle. All Rights Reserved